Opportunity Information: Apply for RFA RM 17 017
The funding opportunity titled "Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54)" is a National Institutes of Health (NIH) initiative designed to strengthen the Undiagnosed Diseases Network by adding a dedicated center focused on rapid functional testing of candidate disease-causing gene variants. Issued as RFA-RM-17-017, this award uses the cooperative agreement mechanism (U54), which generally means the NIH expects to have substantial involvement in coordinating activities, milestones, and network integration rather than simply providing funds with minimal oversight. The program sits within the NIH Common Fund (CFDA 93.310), reflecting its cross-cutting, high-impact intent and its role in accelerating discoveries that can affect many areas of medicine, not just one disease category.
At its core, the grant supports the establishment and operation of a Model Organisms Screening Center for Phase II of the UDN. The Center is expected to evaluate the pathogenicity (whether a variant is actually disease-causing) and biological function of roughly 200 gene variants each year that have been identified through UDN clinical and genomic investigations. This is important because sequencing often finds rare or novel variants that look suspicious but cannot be confidently linked to a patient’s condition without functional evidence. The Center’s job is to close that gap by creating a reliable, scalable pipeline that can move from a prioritized variant list to experimental results that help interpret clinical significance and illuminate disease mechanisms.
Applications are expected to propose a clear screening strategy that explains how the Center will choose the most informative variants to study from among those emerging from the UDN. Since functional testing capacity is finite, the FOA emphasizes the need for rational selection and triage approaches, such as prioritizing variants based on phenotype match, predicted impact on protein function, gene constraint metrics, inheritance patterns, or the feasibility of modeling the variant in experimental systems. The FOA also makes it clear that the funded Center should not be a single-assay operation; it should be a platform with a defined pipeline that can handle volume, support decision-making, and produce interpretable results that feed back into UDN case resolution.
A major requirement is that the research platform include, at minimum, both Drosophila (fruit fly) and zebrafish models. These organisms are widely used in human disease research because they offer complementary strengths: Drosophila enables rapid genetics, powerful variant manipulation, and efficient screening in a living organism, while zebrafish provides a vertebrate context with strong developmental and organ-system relevance, including imaging-friendly embryology that can be valuable for modeling congenital and neurologic phenotypes. The FOA allows, and implicitly encourages when justified, adding other small animal models or cell-based assays to strengthen the pipeline. This could include organisms like C. elegans or mouse for specific questions, as well as in vitro approaches such as patient-derived cells, iPSC-based systems, organoids, or targeted biochemical assays. The guiding principle is that the chosen models and assays should be appropriate for evaluating gene function in a way that maps onto the UDN participant’s disease phenotype, rather than producing generic molecular readouts that are hard to interpret clinically.
The practical expectation is that the Center will operate as a functional genomics hub for the UDN, translating genetic findings into biological and clinically meaningful evidence. For each selected variant, the Center would typically develop or apply assays that test whether the variant disrupts gene function, alters relevant pathways, or reproduces aspects of the patient’s phenotype in the model system. Results from these studies can help reclassify variants of uncertain significance, support diagnoses for rare disease patients, identify new gene-disease relationships, and generate mechanistic insights that might guide future therapeutic research. Because this is framed as a network resource, the work is meant to be systematic and service-oriented in addition to being scientifically rigorous, with an emphasis on throughput, standardization, and timely communication back to the UDN.
In terms of applicant eligibility, the opportunity is broadly open across many domestic organization types, including state, county, and municipal governments; public and state-controlled institutions of higher education; private institutions of higher education; independent school districts; special district governments; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses. The FOA explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities, tribally controlled colleges and universities, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, it draws firm boundaries around non-U.S. applicants: non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as NIH defines them in the NIH Grants Policy Statement, are allowed, meaning a U.S.-based awardee can include certain international collaborations or activities as components of the project if they meet NIH requirements and are well justified.
Administratively, the FOA was created on August 15, 2017, and the original closing date listed is November 2, 2017. The listing does not specify an award ceiling or the number of expected awards in the provided text, but the intent is clearly to fund a center-level capability rather than small, disconnected projects. Overall, this opportunity is aimed at building an integrated, high-throughput functional testing pipeline anchored in model organism biology, tightly coupled to UDN clinical cases, and structured to generate actionable evidence about whether and how rare gene variants contribute to human disease.Apply for RFA RM 17 017
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310.
- This funding opportunity was created on 2017-08-15.
- Applicants must submit their applications by 2017-11-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is the title of this funding opportunity?
The opportunity is titled "Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54)."
2) Which agency is offering this grant?
This is a National Institutes of Health (NIH) funding opportunity.
3) What is the FOA number for this opportunity?
The FOA is issued as RFA-RM-17-017.
4) What funding mechanism is used?
The award uses the cooperative agreement mechanism (U54).
5) What does it mean that this is a cooperative agreement (U54)?
A cooperative agreement generally means NIH expects substantial involvement in coordinating activities, milestones, and integration with the broader network, rather than providing funds with minimal oversight.
6) What larger program is this center intended to support?
The award is designed to strengthen the Undiagnosed Diseases Network (UDN) by adding a dedicated center focused on rapid functional testing of candidate disease-causing gene variants.
7) What NIH program area is this associated with?
The program sits within the NIH Common Fund (CFDA 93.310), reflecting a cross-cutting intent to accelerate discoveries that can affect many areas of medicine.
8) What is the overall purpose of the Model Organisms Screening Center?
The purpose is to establish and operate a center that evaluates the pathogenicity and biological function of candidate disease-causing gene variants identified through UDN clinical and genomic investigations, using a reliable and scalable functional testing pipeline.
9) About how many variants is the Center expected to evaluate each year?
The Center is expected to evaluate roughly 200 gene variants per year.
10) Why is functional testing of variants needed?
Sequencing often identifies rare or novel variants that look suspicious but cannot be confidently linked to a patient's condition without functional evidence. The Center is intended to help close that gap by producing experimental results that support interpretation of clinical significance and disease mechanisms.
11) What is meant by evaluating "pathogenicity" in this context?
In this context, evaluating pathogenicity means testing whether a gene variant is actually disease-causing and how it affects biological function in ways that relate to the UDN participant's phenotype.
12) What kind of approach is NIH expecting applicants to propose for screening?
Applications are expected to propose a clear screening strategy describing how the Center will choose the most informative variants to study from among those emerging from the UDN, acknowledging that functional testing capacity is finite.
13) What examples of variant selection or triage criteria are mentioned?
The FOA emphasizes rational selection and triage approaches, such as prioritizing variants based on phenotype match, predicted impact on protein function, gene constraint metrics, inheritance patterns, and feasibility of modeling the variant in experimental systems.
14) Is the Center expected to run only one assay type?
No. The FOA indicates the Center should not be a single-assay operation. It should be a platform with a defined pipeline that can handle volume, support decision-making, and produce interpretable results that feed back into UDN case resolution.
15) Which model organisms are required at minimum?
The research platform must include, at minimum, both Drosophila (fruit fly) and zebrafish models.
16) Why are Drosophila and zebrafish specifically emphasized?
Drosophila supports rapid genetics, powerful variant manipulation, and efficient screening in a living organism. Zebrafish provides a vertebrate context with strong developmental and organ-system relevance and imaging-friendly embryology, which can be useful for modeling congenital and neurologic phenotypes.
17) Are additional model systems or assay types allowed?
Yes. The FOA allows and encourages (when justified) adding other small animal models or cell-based assays to strengthen the pipeline.
18) What are examples of additional models or assays mentioned as possibilities?
Examples include other organisms such as C. elegans or mouse for specific questions, and in vitro approaches such as patient-derived cells, iPSC-based systems, organoids, targeted biochemical assays, or other cell-based assays.
19) How should the Center choose which models or assays to use?
The guiding principle described is that models and assays should be appropriate for evaluating gene function in a way that maps onto the UDN participant's disease phenotype, rather than producing generic molecular readouts that are difficult to interpret clinically.
20) What kinds of results is the Center expected to generate for each variant?
For each selected variant, the Center would typically develop or apply assays to test whether the variant disrupts gene function, alters relevant pathways, or reproduces aspects of the patient's phenotype in the model system, and then communicate interpretable results back to the UDN.
21) How do the Center's results help UDN participants and the network?
Results can help reclassify variants of uncertain significance, support diagnoses for rare disease patients, identify new gene-disease relationships, and generate mechanistic insights that may guide future therapeutic research.
22) Is this Center intended to function as a network resource?
Yes. The opportunity frames the Center as a functional genomics hub for the UDN, with systematic and service-oriented work alongside scientific rigor, emphasizing throughput, standardization, and timely communication.
23) Who is eligible to apply?
Eligibility is broad across many domestic organization types, including governmental entities (state, county, municipal, special districts), public and state-controlled institutions of higher education, private institutions of higher education, independent school districts, tribal governments and tribal organizations (including those not federally recognized), public housing authorities/Indian housing authorities, nonprofits (with or without 501(c)(3) status), for-profit organizations other than small businesses, and small businesses.
24) Are any specific institution types explicitly highlighted as eligible?
Yes. The FOA highlights categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based or community-based organizations, Hispanic-serving institutions, historically Black colleges and universities, tribally controlled colleges and universities, regional organizations, eligible federal agencies, and U.S. territories or possessions.
25) Are non-U.S. (non-domestic) entities eligible to apply?
No. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply.
26) Are foreign components permitted at all?
Yes. Foreign components (as defined in the NIH Grants Policy Statement) are allowed, meaning a U.S.-based awardee may include certain international collaborations or activities as components of the project if they meet NIH requirements and are well justified.
27) When was this FOA created?
The FOA was created on August 15, 2017.
28) What is the closing date listed in the provided information?
The original closing date listed is November 2, 2017.
29) Does the provided information state an award ceiling?
No. The provided text does not specify an award ceiling.
30) Does the provided information state how many awards NIH expects to make?
No. The provided text does not specify the number of expected awards.
31) What kind of project scale does this opportunity appear to target?
Based on the description, the intent is to fund a center-level capability (an integrated, high-throughput functional testing pipeline) rather than small, disconnected projects.
32) What is the core operational expectation for the Center within UDN Phase II?
The Center is expected to run a systematic pipeline that can move from a prioritized variant list to experimental results, operating with throughput, standardization, and timely communication so findings feed back into UDN case resolution.
Browse more opportunities from the same category: Health
Next opportunity: Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
Previous opportunity: NEA Art Works II Application, FY2018
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 17 017
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 17 017) also looked into and applied for these:
| Funding Opportunity |
|---|
| Coordinating Center for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 018 Funding Number: RFA RM 17 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Sites for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 019 Funding Number: RFA RM 17 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sequencing Core(s) for the Undiagnosed Diseases Network (UDN) Phase II (U01) Apply for RFA RM 17 016 Funding Number: RFA RM 17 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for Countermeasures Against Select Pathogens (R01) Apply for RFA AI 17 026 Funding Number: RFA AI 17 026 Agency: National Institutes of Health Category: Health Funding Amount: $1,050,000 |
| Continuation of Existing Grant Based Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01) Apply for PAR 17 338 Funding Number: PAR 17 338 Agency: National Institutes of Health Category: Health Funding Amount: $1,950,000 |
| Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies (Collaborative U01) Apply for RFA AA 18 002 Funding Number: RFA AA 18 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcoholic Hepatitis Clinical and Translational Network Translational Research (U01) Apply for RFA AA 18 003 Funding Number: RFA AA 18 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcoholic Hepatitis Clinical and Translational Network Data Coordinating Center (U24) Apply for RFA AA 18 004 Funding Number: RFA AA 18 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Existing Alcohol Research Data (R01) Apply for PA 17 467 Funding Number: PA 17 467 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Secondary Analyses of Existing Alcohol Research Data (R03) Apply for PA 17 468 Funding Number: PA 17 468 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| Alcoholic Hepatitis Clinical and Translational Network Clinical Pilot Trials (U01) Apply for RFA AA 18 005 Funding Number: RFA AA 18 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcoholic Hepatitis Clinical and Translational Network Basic and Pre-Clinical Research (UH2/UH3) Apply for RFA AA 18 006 Funding Number: RFA AA 18 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Centers in Minority Institutions (RCMI) (U54) Apply for RFA MD 17 006 Funding Number: RFA MD 17 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Coinfection Surveillance Strategies for Program Planning in Central America and Panama Region in Guatemala Apply for CDC RFA GH13 134405CONT18 Funding Number: CDC RFA GH13 134405CONT18 Agency: Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Strengthening Clinical Services of PLHIV in Central America under PEPFAR Apply for CDC RFA GH17 177602CONT18 Funding Number: CDC RFA GH17 177602CONT18 Agency: Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Building Capacity along the Continuum from Prevention to Care and Treatment for Key Populations in the Central America Region under PEPFAR Apply for CDC RFA GH15 151004CONT18 Funding Number: CDC RFA GH15 151004CONT18 Agency: Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Establishment of a Strategic Partnership to Strengthen the COMISCA under PEPFAR Apply for CDC RFA GH15 150904CONT18 Funding Number: CDC RFA GH15 150904CONT18 Agency: Centers for Disease Control - CGH Category: Health Funding Amount: Case Dependent |
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01) Apply for PAR 17 466 Funding Number: PAR 17 466 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R21) Apply for PAR 17 463 Funding Number: PAR 17 463 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (R21) Apply for PAR 17 474 Funding Number: PAR 17 474 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 17 017", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.